Updated

Updated · PR Newswire · Aug 10

MDD Market Seen Growing From $7.8 Billion as Novel Antidepressants Advance Through 2036

Updated

Updated · PR Newswire · Aug 10

MDD Market Seen Growing From $7.8 Billion as Novel Antidepressants Advance Through 2036

1 articles · Updated · PR Newswire · Aug 10

DelveInsight projects the major depressive disorder market to expand through 2036, with the 7 major markets valued at $7.8 billion in 2025 and new therapies expected to widen treatment options.
About 44 million diagnosed MDD cases across the 7MM in 2025 underpin that outlook, while demand is rising for faster-acting drugs that can help treatment-resistant patients or those underserved by SSRIs and SNRIs.
Late-stage and emerging candidates including Johnson & Johnson's seltorexant, Xenon's azetukalner and VistaGen's itruvone are being developed to improve speed, efficacy and tolerability, intensifying competition in the category.
The U.S. remains the largest market and patient pool, with roughly 22 million diagnosed cases in 2025, while marketed products such as SPRAVATO, AUVELITY and CAPLYTA are already reshaping the treatment landscape.

Sources

Center100%

If a highly anticipated depression drug misses its primary trial endpoint, why are investors still betting billions on its success?

Could breakthrough rapid-acting depression treatments be derailed by strict insurance denials before they even reach patients?

Will precision psychiatry and brain-mapping biomarkers finally end the exhausting trial-and-error era of antidepressant prescribing?

1 total

Center100%